Crossmark

Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck

Crossref DOI link: https://doi.org/10.1007/s00405-025-09655-8

Published Online: 2025-09-03

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beyaert, Simon https://orcid.org/0000-0002-7241-526X
Loriot, Axelle

Magremanne, Michèle

Renwart, William

Mahy, Pierre

Duprez, Thierry

Baldin, Pamela

Benidovskaya, Elena

Huyghe, Nicolas

Dahou, Hajar

Stroobant, Vincent

Gomard, Tiphanie

Machiels, Jean-Pascal

Schmitz, Sandra
License Information

Text and Data Mining valid from 2025-09-03

Version of Record valid from 2025-09-03
More Information

Article History

Received: 12 April 2025

Accepted: 11 August 2025

First Online: 3 September 2025

Declarations

:

: The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice standard and the Declaration of Helsinki.

: All patients signed an informed consent to participate in a drug study with prospective collection of biological material.

: JP Machiels reports grants from Boehringer-Ingelheim during the conduct of the study; and other support from Pfizer, Roche, AstraZeneca, Bayer, Innate, Merck Serono, Boehringer, BMS, Novartis, Janssen, Incyte, Cue Biopharma, ALX oncology, iTEOS, eTheRNA, NEKTAR, F-star, Seagen, Genmab, Astellas, CureVac, MSD, Gilead, and Sanofi outside the submitted work. S. No disclosures were reported by the other authors.

Document is current

Any future updates will be listed below